Mechanism and therapeutic effects of Saccharomyces boulardii on experimental colitis in mice

Zhou,Huan; Zhang,Hui‑Jing; Guan,Lin; Zhang,Yi‑Ning; Li,Yue; Sun,Ming‑Jun

doi:10.3892/mmr.2018.9612

Mechanism and therapeutic effects of Saccharomyces boulardii on experimental colitis in mice

Authors:
- Huan Zhou
- Hui‑Jing Zhang
- Lin Guan
- Yi‑Ning Zhang
- Yue Li
- Ming‑Jun Sun
View Affiliations

Affiliations: Department of Gastroenterology and Endoscopy, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 11000, P.R. China
Published online on: October 30, 2018 https://doi.org/10.3892/mmr.2018.9612
Pages: 5652-5662
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammatory bowel disease (IBD) is a type of chronic inflammatory disturbance that affects a number of individuals worldwide; the precise mechanism is unclear and treatment is frequently insufficient to maintain patients in remission. Saccharomyces boulardii is a thermophilic, non‑pathogenic yeast that may be administered for prophylaxis and treatment of a variety of diarrheal diseases. Recent clinical studies have demonstrated that it may have a role in IBD; however, the mechanism of action is unclear. The hypoxia‑inducible factors (HIFs) are ubiquitously expressed regulators of cellular adaptation to hypoxia and are central to the adaptive and inflammatory responses of cells of the intestinal mucosa in patients with IBD. The present study aimed to investigate the effects of S. boulardii on dextran sulfate sodium (DSS)‑induced colitis in mice and the effects of S. boulardii on HIFs. Mice were divided into five groups (n=10 mice/group): i) Control; ii) DSS; iii) S. boulardii (Sb) + DSS; iv) normal saline (NS) + DSS; and v) Sb. For 14 consecutive days, mice from the Sb+DSS and Sb groups were given S. boulardii suspension in saline (150 mg/kg/day; final volume 0.2 ml) by oral gavage. The NS+DSS group received the same volume of NS by gavage. The Control mice received water only. From day 8 to day 14, 3.5% DSS was added to the drinking water of the DSS, Sb+DSS and NS+DSS groups to induce acute colitis. Body weight decreased and disease activity index and histological score increased in mice with DSS‑induced colitis. Oral administration of S. boulardii reduced DSS‑induced weight loss, ameliorated the histological damage and protected the colon barrier in mice with DSS‑induced colitis. The expression of HIF‑1α and HIF‑2α in colon tissues was measured by reverse transcription‑quantitative polymerase chain reaction, immunoblotting and immunohistochemistry. The increase in HIFs in the colon induced by DSS was significantly inhibited by S. boulardii treatment. The expression levels of several epithelial‑mesenchymal transition (EMT) markers and of vascular endothelial growth factor (VEGF) that are regulated by HIFs were measured. S. boulardii reduced EMT and decreased expression of VEGF that was induced by DSS treatment. These results indicated that treatment with S. boulardii ameliorated DSS‑induced colitis, partly through downregulation of HIF‑1α and HIF‑2α.

View Figures

View References

1	Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, et al: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 142:46–54, e42; quiz e30. 2012. View Article : Google Scholar : PubMed/NCBI
2	Shah YM: The role of hypoxia in intestinal inflammation. Mol Cell Pediatr. 3:12016. View Article : Google Scholar : PubMed/NCBI
3	Fagundes RR and Taylor CT: Determinants of hypoxia-inducible factor activity in the intestinal mucosa. J Appl Physiol. 123:1328–1334. 2017. View Article : Google Scholar : PubMed/NCBI
4	Cummins EP and Crean D: Hypoxia and inflammatory bowel disease. Microbes Infect. 19:210–221. 2017. View Article : Google Scholar : PubMed/NCBI
5	Reiff C and Kelly D: Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol. 300:25–33. 2010. View Article : Google Scholar : PubMed/NCBI
6	Guandalini S: Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease. Expert Rev Clin Immunol. 6:47–54. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yu CG and Huang Q: Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease. J Dig Dis. 14:513–517. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hold GL, Smith M, Grange C, Watt ER, El-Omar EM and Mukhopadhya I: Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years? World J Gastroenterol. 20:1192–1210. 2014. View Article : Google Scholar : PubMed/NCBI
9	Hatoum R, Labrie S and Fliss I: Antimicrobial and probiotic properties of yeasts: From fundamental to novel applications. Front Microbiol. 3:4212012. View Article : Google Scholar : PubMed/NCBI
10	Generoso SV, Viana M, Santos R, Martins FS, Machado JA, Arantes RM, Nicoli JR, Correia MI and Cardoso VN: Saccharomyces cerevisiae strain UFMG 905 protects against bacterial translocation, preserves gut barrier integrity and stimulates the immune system in a murine intestinal obstruction model. Arch Microbiol. 192:477–484. 2010. View Article : Google Scholar : PubMed/NCBI
11	Buts JP and De Keyser N: Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci. 51:1485–1492. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kelesidis T and Pothoulakis C: Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 5:111–125. 2012. View Article : Google Scholar : PubMed/NCBI
13	Guslandi M, Mezzi G, Sorghi M and Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 45:1462–1464. 2000. View Article : Google Scholar : PubMed/NCBI
14	Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S and Katsu K: Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol. 117:462–468. 1999. View Article : Google Scholar : PubMed/NCBI
15	Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238–249. 1993.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	McCole DF: IBD candidate genes and intestinal barrier regulation. Inflamm Bowel Dis. 20:1829–1849. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kim YE, Lee M, Gu H, Kim J, Jeong S, Yeo S, Lee YJ, Im SH, Sung YC, Kim HJ, et al: HIF-1α activation in myeloid cells accelerates dextran sodium sulfate-induced colitis progression in mice. Dis Model Mech. 11:112018. View Article : Google Scholar
19	Kim SL, Park YR, Lee ST and Kim SW: Parthenolide suppresses hypoxia-inducible factor-1α signaling and hypoxia induced epithelial-mesenchymal transition in colorectal cancer. Int J Oncol. 51:1809–1820. 2017. View Article : Google Scholar : PubMed/NCBI
20	Feng N, Chen H, Fu S, Bian Z, Lin X, Yang L, Gao Y, Fang J and Ge Z: HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide. Sci Rep. 6:272802016. View Article : Google Scholar : PubMed/NCBI
21	Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 11:506–514. 2014. View Article : Google Scholar : PubMed/NCBI
22	Generoso SV, Viana ML, Santos RG, Arantes RM, Martins FS, Nicoli JR, Machado JA, Correia MI and Cardoso VN: Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr. 50:261–269. 2011. View Article : Google Scholar : PubMed/NCBI
23	Terciolo C, Dobric A, Ouaissi M, Siret C, Breuzard G, Silvy F, Marchiori B, Germain S, Bonier R, Hama A, et al: Saccharomyces boulardii CNCM I-745 Restores intestinal Barrier Integrity by Regulation of E-cadherin Recycling. J Crohn's Colitis. 11:999–1010. 2017. View Article : Google Scholar
24	Glover LE and Colgan SP: Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology. 140:1748–1755. 2011. View Article : Google Scholar : PubMed/NCBI
25	Flück K and Fandrey J: Oxygen sensing in intestinal mucosal inflammation. Pflugers Arch. 468:77–84. 2016. View Article : Google Scholar : PubMed/NCBI
26	Colgan SP and Taylor CT: Hypoxia: An alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol. 7:281–287. 2010. View Article : Google Scholar : PubMed/NCBI
27	Joseph JP, Harishankar MK, Pillai AA and Devi A: Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 80:23–32. 2018. View Article : Google Scholar : PubMed/NCBI
28	Scharl M, Weber A, Fürst A, Farkas S, Jehle E, Pesch T, Kellermeier S, Fried M and Rogler G: Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflamm Bowel Dis. 17:1907–1916. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yang SW, Zhang ZG, Hao YX, Zhao YL, Qian F, Shi Y, Li PA, Liu CY and Yu PW: HIF-1α induces the epithelial-mesenchymal transition in gastric cancer stem cells through the Snail pathway. Oncotarget. 8:9535–9545. 2017.PubMed/NCBI
30	Chen S, Chen JZ, Zhang JQ, Chen HX, Yan ML, Huang L, Tian YF, Chen YL and Wang YD: Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice. Cancer Lett. 383:73–84. 2016. View Article : Google Scholar : PubMed/NCBI
31	Karayiannakis AJ, Syrigos KN, Efstathiou J, Valizadeh A, Noda M, Playford RJ, Kmiot W and Pignatelli M: Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. J Pathol. 185:413–418. 1998. View Article : Google Scholar : PubMed/NCBI
32	Mehta S, Nijhuis A, Kumagai T, Lindsay J and Silver A: Defects in the adherens junction complex (E-cadherin/β-catenin) in inflammatory bowel disease. Cell Tissue Res. 360:749–760. 2015. View Article : Google Scholar : PubMed/NCBI
33	Ippolito C, Colucci R, Segnani C, Errede M, Girolamo F, Virgintino D, Dolfi A, Tirotta E, Buccianti P, Di Candio G, et al: Fibrotic and vascular remodelling of colonic wall in patients with active ulcerative colitis. J Crohn's Colitis. 10:1194–1204. 2016. View Article : Google Scholar
34	Andoh A, Fujino S, Okuno T, Fujiyama Y and Bamba T: Intestinal subepithelial myofibroblasts in inflammatory bowel diseases. J Gastroenterol. 37 Suppl 14:S33–S37. 2002. View Article : Google Scholar
35	Xue X, Ramakrishnan S, Anderson E, Taylor M, Zimmermann EM, Spence JR, Huang S, Greenson JK and Shah YM: Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology. 145:831–841. 2013. View Article : Google Scholar : PubMed/NCBI
36	Tang X, Yang Y, Yuan H, You J, Burkatovskaya M and Amar S: Novel transcriptional regulation of VEGF in inflammatory processes. J Cell Mol Med. 17:386–397. 2013. View Article : Google Scholar : PubMed/NCBI
37	Chen X, Yang G, Song JH, Xu H, Li D, Goldsmith J, Zeng H, Parsons-Wingerter PA, Reinecker HC and Kelly CP: Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation. PLoS One. 8:e642272013. View Article : Google Scholar : PubMed/NCBI
38	Skuli N, Majmundar AJ, Krock BL, Mesquita RC, Mathew LK, Quinn ZL, Runge A, Liu L, Kim MN, Liang J, et al: Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J Clin Invest. 122:1427–1443. 2012. View Article : Google Scholar : PubMed/NCBI
39	Ramakrishnan S, Anand V and Roy S: Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol. 9:142–160. 2014. View Article : Google Scholar : PubMed/NCBI